Valuation : CEL-SCI Corporation

Market Cap 27.44M 23.64M 22.17M 20.24M 38.12M 2.62B 38.24M 263M 103M 1.32B 103M 101M 4.39B P/E 2026 *
-0.51x
P/E 2027 * -0.24x
Enterprise Value 21.88M 18.86M 17.68M 16.14M 30.41M 2.09B 30.5M 210M 81.85M 1.06B 82.17M 80.38M 3.5B EV / Sales 2026 *
-
EV / Sales 2027 * 3.7x
Free-Float
93.16%
Yield 2026 *
-
Yield 2027 * -
1 day-2.50%
1 week+9.86%
Current month+34.48%
1 month+27.87%
3 months+1.30%
6 months-59.27%
Current year-70.34%
1 week 1.37
Extreme 1.3701
1.7
1 month 1.15
Extreme 1.15
1.75
Current year 0.89
Extreme 0.89
6.75
1 year 0.89
Extreme 0.89
12.68
3 years 0.89
Extreme 0.89
96.91
5 years 0.89
Extreme 0.89
387.04
10 years 0.89
Extreme 0.89
1,227.42
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Date Insider Type Main position Quantity % Market Cap.
25/08/26 Buy

Chief Executive Officer

100,000 0.5722%
14/08/26 Free

Chief Financial Officer

225,000 1.2874%
14/08/26 Free

Director

110,000 0.6294%
Change 5-day change 1-year change 3-year change Capi.($)
-2.50%+9.86%-85.04%-96.29% 27.44M
-1.59%-3.35%+52.37%+91.62% 69.54B
-2.23%+1.32%+44.54%+88.38% 64.97B
-3.57%+0.49%+35.74%+10.62% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-1.39%+0.85%+29.84%-19.32% 19.98B
-3.36%-4.93%+2.30%+549.93% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -2.78%-0.75%+39.75%+161.45% 28.2B
Weighted average by Cap. -2.63%-1.50%+50.26%+149.18%

Financials

2026 *2027 *
Net sales - 5.97M 5.15M 4.82M 4.4M 8.3M 571M 8.32M 57.24M 22.33M 288M 22.42M 21.93M 955M
Net income -25.08M -21.61M -20.27M -18.5M -34.85M -2.4B -34.96M -240M -93.81M -1.21B -94.18M -92.13M -4.01B -29.51M -25.43M -23.85M -21.77M -41.01M -2.82B -41.14M -283M -110M -1.42B -111M -108M -4.72B
Net Debt -5.55M -4.79M -4.49M -4.1M -7.72M -531M -7.74M -53.24M -20.77M -268M -20.85M -20.4M -888M -5.34M -4.6M -4.31M -3.94M -7.42M -510M -7.44M -51.18M -19.97M -258M -20.05M -19.61M -854M
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
44
Date Price Change Volume
28/08/26 $1.560 -2.50% 170,340
27/08/26 $1.600 -0.62% 161,622
26/08/26 $1.610 +8.78% 263,050
25/08/26 $1.480 +7.25% 86,443
24/08/26 $1.380 -2.82% 149,139
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.560USD
Average target price
12.50USD
Spread / Average Target
+701.28%

Annual profits - Rate of surprise